BRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024

Reuters

2024/10/28

Oct 28 (Reuters) - Ironwood Pharmaceuticals Inc

* ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024

* IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION IN Q1 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2478101422"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478101422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478101422?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478101422","market":"us","top_or_hot":-1,"title":"BRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024","media":"Reuters","content":"<html><body><p>Oct 28 (Reuters) - Ironwood Pharmaceuticals Inc</p><p> :</p><p>   * ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024</p><p>   * IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION IN Q1 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-28 19:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Oct 28 (Reuters) - Ironwood Pharmaceuticals Inc</p><p> :</p><p>   * ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024</p><p>   * IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION IN Q1 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2478101422","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478101422","pubTimestamp":1730116595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 28  - Ironwood Pharmaceuticals Inc :   * ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE , ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024   * IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION IN Q1 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药","BK4139":"生物科技"},"translate_title":"根据Acg 2024上Ironwood的New STARS III期数据，每周一次的Apraglutide在患有短肠综合征伴肠衰竭(Sbs-If)的成人患者的基线人口统计学和疾病特征方面显示出一致的治疗效果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":0.9},"content_text":"Oct 28 (Reuters) - Ironwood Pharmaceuticals Inc :   * ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024   * IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION IN Q1 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}